Research Landscape: Endocrine Therapies for ER+/HER2- Metastatic Breast Cancer

FDA approved the monotherapy for estrogen receptor (ER)–positive and HER2-negative metastatic breast cancer.

Breast cancer is the second most common cancer among women and the second leading cause of cancer-related deaths among women in the US. In light of Breast Cancer Research Awareness Day, The American Journal of Managed Care® breaks down the most recent advancements in breast cancer prevention, screening, and therapies.

The Breast Cancer Index and artificial intelligence–assisted mammograms are tools that can help mitigate symptoms and reassure patient insecurities of women with breast cancer post-treatment.

Sadie Dobrozsi, MD, of Evolent, discusses how predictive genomics is pushing cancer care into a new era of personalization

RIsing costs for therapies and inequities in reimbursement for genomic testing have created financial barriers for patients, according to appearing experts in Detroit, Michigan, on July 10, 2025.

New research reveals how triple-negative breast tumors use fatty tissue to fuel growth, highlighting the role of gap junctions in tumorigenesis.